# Medline Inc.: financial statements, quarterly

MDLN · Nasdaq · CIK 2046386 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mdln.md) · [Financials](/companies/mdln/financials.md) · [Filings](/companies/mdln/filings.md) · [Insiders](/companies/mdln/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mdln/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-29) | period not labelled (2025-06-28) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [6,644](/filings/0002046386-26-000026.md) | [6,886](/filings/0002046386-26-000051.md) | [7,352](/filings/0002046386-26-000026.md) | [7,685](/filings/0002046386-26-000051.md) |
| Cost of revenue | $m | [4,820](/filings/0002046386-26-000026.md) | [4,981](/filings/0002046386-26-000051.md) | [5,511](/filings/0002046386-26-000026.md) | [5,470](/filings/0002046386-26-000051.md) |
| Gross profit | $m | [1,824](/filings/0002046386-26-000026.md) | [1,905](/filings/0002046386-26-000051.md) | [1,841](/filings/0002046386-26-000026.md) | [2,215](/filings/0002046386-26-000051.md) |
| Selling, general and administrative | $m | [1,070](/filings/0002046386-26-000026.md) | [1,073](/filings/0002046386-26-000051.md) | [1,228](/filings/0002046386-26-000026.md) | [1,295](/filings/0002046386-26-000051.md) |
| Operating income | $m | [571](/filings/0002046386-26-000026.md) | [642](/filings/0002046386-26-000051.md) | [422](/filings/0002046386-26-000026.md) | [395](/filings/0002046386-26-000051.md) |
| Interest expense | $m | [244](/filings/0002046386-26-000026.md) | [253](/filings/0002046386-26-000051.md) | [165](/filings/0002046386-26-000026.md) | [168](/filings/0002046386-26-000051.md) |
| Income tax | $m | [16.0](/filings/0002046386-26-000026.md) | [26.0](/filings/0002046386-26-000051.md) | [52.0](/filings/0002046386-26-000026.md) | [96.0](/filings/0002046386-26-000051.md) |
| Net income | $m | [319](/filings/0002046386-26-000051.md) | [329](/filings/0002046386-26-000051.md) | [239](/filings/0002046386-26-000051.md) | [139](/filings/0002046386-26-000051.md) |
| Diluted EPS | $ per share | not reported | not reported | [0.16](/filings/0002046386-26-000026.md) | [0.07](/filings/0002046386-26-000051.md) |
| Basic EPS | $ per share | not reported | not reported | [0.16](/filings/0002046386-26-000026.md) | [0.07](/filings/0002046386-26-000051.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-12-31) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.2](/filings/0002046386-26-000009.md) | [1.9](/filings/0002046386-26-000051.md) | [2.2](/filings/0002046386-26-000026.md) | [2.3](/filings/0002046386-26-000051.md) |
| Current assets | $bn | [8.3](/filings/0002046386-26-000009.md) | [10.7](/filings/0002046386-26-000051.md) | [11.2](/filings/0002046386-26-000026.md) | [11.7](/filings/0002046386-26-000051.md) |
| Total assets | $bn | [36.0](/filings/0002046386-26-000009.md) | [38.5](/filings/0002046386-26-000051.md) | [39.0](/filings/0002046386-26-000026.md) | [39.4](/filings/0002046386-26-000051.md) |
| Current liabilities | $bn | [2.4](/filings/0002046386-26-000009.md) | [2.5](/filings/0002046386-26-000051.md) | [2.5](/filings/0002046386-26-000026.md) | [2.7](/filings/0002046386-26-000051.md) |
| Total liabilities | $bn | [19.5](/filings/0002046386-26-000009.md) | [19.2](/filings/0002046386-26-000051.md) | [19.7](/filings/0002046386-26-000026.md) | [20.3](/filings/0002046386-26-000051.md) |
| Long-term debt | $bn | [16.4](/filings/0002046386-26-000009.md) | [12.5](/filings/0002046386-26-000051.md) | [12.5](/filings/0002046386-26-000026.md) | [12.5](/filings/0002046386-26-000051.md) |
| Current portion of debt | $bn | [0.1](/filings/0002046386-26-000009.md) | [0.1](/filings/0002046386-26-000051.md) | [0.1](/filings/0002046386-26-000026.md) | [0.0](/filings/0002046386-26-000051.md) |
| Short-term borrowings | $bn | [0.0](/filings/0002046386-26-000009.md) | [0.0](/filings/0002046386-26-000051.md) | [0.0](/filings/0002046386-26-000026.md) | [0.0](/filings/0002046386-26-000051.md) |
| Shareholders' equity | $bn | not reported | [10.7](/filings/0002046386-26-000051.md) | [11.3](/filings/0002046386-26-000026.md) | [11.6](/filings/0002046386-26-000051.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-29) | period not labelled (2025-06-28) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [682](/filings/0002046386-26-000026.md) | [197 d](/filings/0002046386-26-000051.md) | [412](/filings/0002046386-26-000026.md) | [715 d](/filings/0002046386-26-000051.md) |
| Capital expenditure | $m | [98.0](/filings/0002046386-26-000026.md) | [110 d](/filings/0002046386-26-000051.md) | [96.0](/filings/0002046386-26-000026.md) | [111 d](/filings/0002046386-26-000051.md) |
| Share repurchases | $m | [9.0](/filings/0002046386-26-000026.md) | [6.0 d](/filings/0002046386-26-000051.md) | [0.0](/filings/0002046386-26-000026.md) | [0.0 d](/filings/0002046386-26-000051.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) |
| --- | --- | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [825](/filings/0002046386-26-000026.md) | [861](/filings/0002046386-26-000051.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.